NYSE:BSX
Boston Scientific Corp.
Boston Scientific Corp.'s revenue grew 19.9% in fiscal 2025 to $20.1B while operating margin rose to 18.0%, its highest in 10 years. Free cash flow was $3.7B, 18.2% of revenue, and the diluted share count rose 0.6%.Summary generated from Boston Scientific Corp.'s SEC filings. Latest annual report filed Feb 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$20.1B
Revenue growth+19.9%
Revenue, 5-yr CAGR+15.2%
Gross margin69.0%
Operating margin18.0%
Net margin14.4%
ROIC9.7%
Return on equity12.6%
Debt / equity0.46
Free cash flow$3.7B
FCF margin18.2%
Share count change+0.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 11.9 | 12.7 | 14.2 | 16.7 | 20.1 |
| Operating income | 1.2 | 1.6 | 2.3 | 2.6 | 3.6 |
| Net income | 1.0 | 0.7 | 1.6 | 1.8 | 2.9 |
| Free cash flow | 1.3 | 0.9 | 1.8 | 2.6 | 3.7 |
Recent filings
- 8-KDirector or officer change
Oct 7, 2026 - 8-KDirector or officer change
Sep 23, 2026 - 8-KCurrent report
Sep 8, 2026 - 4Insider transaction report
Sep 3, 2026 - 4Insider transaction report
Aug 26, 2026 - 8-KOther events
Aug 26, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 3, 2026 - 8-KResults of operations and financial condition
Jul 29, 2026